Real-world survival of Danish patients with HER2-positive metastatic breast cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Deluche E, Antoine A, Bachelot T, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer. 2020;129:60–70. doi: 10.1016/j.ejca.2020.01.016.
   PubMed Web of Science ®Google Scholar
• Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian breast cancer study group. J Clin Oncol. 1993;11(10):1936–1942. doi: 10.1200/JCO.1993.11.10.1936.
   PubMed Web of Science ®Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Franzoi MAB, Temin S, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(23):2612–2635. doi: 10.1200/JCO.22.00519.
   PubMed Web of Science ®Google Scholar
• Lee SS, Ahn J-H, Kim MK, et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat. 2008;111(3):523–530. doi: 10.1007/s10549-007-9806-2.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Watanabe J, Mitsuya K, et al. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Res Treat. 2017;162(1):169–179. doi: 10.1007/s10549-017-4107-x.
   PubMed Web of Science ®Google Scholar
• Ramakrishna N, Anders CK, Lin NU, et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol. 2022;40(23):2636–2655. doi: 10.1200/JCO.22.00520.
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim S-B, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–471. doi: 10.1016/S1470-2045(13)70130-X.
   PubMed Web of Science ®Google Scholar
• Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264–271. doi: 10.1200/JCO.2010.30.8213.
   PubMed Web of Science ®Google Scholar
• Swain SM, Miles D, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530. doi: 10.1016/S1470-2045(19)30863-0.
   PubMed Web of Science ®Google Scholar
• Christensen T, Berg T, Nielsen LB, et al. Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients. Breast. 2020;51:34–39. Jundoi: 10.1016/j.breast.2020.03.002.
   PubMed Web of Science ®Google Scholar
• Maurer C, Tulpin L, Moreau M, et al. Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. ESMO Open. 2018;3(6):e000440. doi: 10.1136/esmoopen-2018-000440.
   PubMed Web of Science ®Google Scholar
• Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases. JAMA Oncol. 2023;9(2):197–205. doi: 10.1001/jamaoncol.2022.5610.
   PubMed Web of Science ®Google Scholar
• Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–1847. doi: 10.1038/s41591-022-01935-8.
   PubMed Web of Science ®Google Scholar